250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Life Science Startup Investors in United States

A list of 50 angel investors and VC funds that invest in Life science startups based in United states. We rank investors based on the number of investments they made in Life science companies from United states. We update this investor list every month.

Top 50 Life Science Startup Investors in United States

Investor Life Science United States investments
ARCH Venture Partners 23
Northpond Ventures 19
Alexandria Venture Investments 18
Novartis Venture Fund 14
RA Capital Management 12
8VC 11
Fifty Years 11
Third Rock Ventures 11
Hatteras Venture Partners 11
OrbiMed 10
Alix Ventures 10
Sahsen Ventures 10
5AM Ventures 10
MPM Capital 10
Atlas Venture 10
DCVC 9
KdT Ventures 9
Civilization Ventures 9
Andreessen Horowitz 9
Google Ventures 9
SR One 9
Rev1 Ventures 9
Versant Ventures 9
Longwood Fund 9
Playground Global 8
Apple Tree Partners 8
iSelect Fund 8
New Enterprise Associates 8
Vivo Capital 8
Lux Capital 7
Flagship Pioneering 7
The Column Group 7
Horizons Ventures 7
Connecticut Innovations 7
Roche Venture Fund 7
Breakout Ventures 7
Illumina Ventures 7
Dolby Family Ventures 7
Artis Ventures (AV) 7
Foresite Capital 7
Alumni Ventures 6
Felicis 6
Omega Funds 6
RiverVest 6
AbbVie Biotech Ventures 6
Oreilly AlphaTech Ventures 6
Vida Ventures 6
Two Sigma Ventures 6
JDRF T1D Fund 6
Boxer Capital 6
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
ARCH Venture Partners VC Fund · Chicago, Illinois, United States · 19 investments in the past 12 months
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, China, United Kingdom
Portfolio highlights
  • Vilya — Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease. The company aims to create new medicines to leverage computing to make high throughput screening obsolete and cure diseases.
  • Metsera — Metsera operates as a clinical-stage biopharmaceutical company.
  • Xaira Therapeutics — Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research tobetter understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
Northpond Ventures VC Fund · Bethesda, Maryland, United States · 8 investments in the past 12 months
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
  • Biotechnology, Health Care, Life Science
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Totus Medicines — Applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.
  • SeLux Diagnostics — SeLux Diagnostics is a developer of the Next-Generation Phenotyping (NGP) platform that enables personalized antibiotic therapies for patients. The company was founded in 2014 and is based in Charlestown, MA.
  • Elephas — Elephas is a live tumor imaging company developing novel cancer diagnostic solutions to predict treatment outcomes and accelerate drug development.
Alexandria Venture Investments VC Fund · Pasadena, California, United States · 13 investments in the past 12 months
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, France, Canada
Portfolio highlights
  • Umaro Foods — Umaro Foods specializes in developing a plant-based protein source from ocean-farmed seaweed.
  • Tome Biosciences — Tome Biosciences is a biotechnology company that develops programmable gene insertion technology. Using CRISPR, its technologies allow them to insert any genetic sequence of any size at any location into any genome.
  • Remix Therapeutics — Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
Novartis Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland · 4 investments in the past 12 months
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
  • Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.
  • Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
RA Capital Management VC Fund · Boston, Massachusetts, United States · 68 investments in the past 12 months
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series C, Series A
  • United States, United Kingdom, China
Portfolio highlights
  • Gameto — Gameto is a new breed of biotechnology company in female reproductive longevity
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • Bicycle Therapeutics — Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
8VC VC Fund · San Francisco, California, United States · 43 investments in the past 12 months
8VC seeks to enable industry transformation. In a wave of creative destruction, they believe emerging platforms will replace the decades-old technology infrastructure behind many industries, promoting greater innovation and prosperity.
Show more
Investment focus
  • Software, Health Care, Information Technology
  • Seed, Series A, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • Vercel — Vercel's Frontend Cloud gives developers the frameworks, workflows, and infrastructure to build a faster, more personalized web.
  • Numeric — Hundreds of teams streamline reconciliations, organize their close, and leverage AI for flux analysis and reporting with Numeric.
  • Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
Fifty Years VC Fund · San Francisco, California, United States · 8 investments in the past 12 months
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, Germany, Canada
Portfolio highlights
  • Nabla Bio — Nabla is an autoreverse platform that enables the rapid discovery of previously unattainable protein variants with supernatural qualities. Nabla Bio makes new medicines and improve nutrition by engineering novel proteins.
  • The Bot Company — The Bot Company a household robot startup.
  • Cosmic Aerospace — Cosmic Aerospace is a pioneering aerospace technology company dedicated to advancing the boundaries of propulsion systems and enabling innovative solutions for space exploration. The company collaborates with leading space agencies, research institutions, and commercial partners to design, test, and implement these groundbreaking technologies.
Third Rock Ventures VC Fund · Boston, Massachusetts, United States · 3 investments in the past 12 months
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
  • Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
  • Synnovation Therapeutics — Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers. It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small-molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.
Hatteras Venture Partners VC Fund · Durham, North Carolina, United States
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Funding Round
  • United States, Canada
Portfolio highlights
  • 410 Medical — 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina.
  • Myeloid Therapeutics — Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.
  • Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
OrbiMed VC Fund · New York, New York, United States · 46 investments in the past 12 months
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States, China, Israel
Portfolio highlights
  • TriSalus Life Sciences — Surefire Medical, based in Westminster, Colorado, was founded in 2009 to develop a novel infusion system for the interventional radiology market. The Surefire's Infusion System is designed to precisely deliver embolic agents through the sophisticated expandable tip portion of its catheter. Because of this differentiated expandable tip, whichcollapses in forwarding flow to maintain blood flow and dynamically expands to the vessel wall in reverse flow to minimize reflux, Surefire's Infusion System is designed to substantially reduce damage to healthy tissue.
  • Corvus Pharmaceuticals — Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
  • Sparrow Pharmaceuticals — Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess.
Alix Ventures VC Fund · San Francisco, California, United States · 2 investments in the past 12 months
Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....
Show more
Investment focus
  • Biotechnology, Health Care, Life Science
  • Seed, Series A, Pre-Seed
  • United States
Portfolio highlights
  • Xilis — Xilis is an oncology and precision health company that diagnoses cancer and finds the right treatment. The company uses “micro-organoids” to make thousands of 3D replicas of a patient’s tumor in about six days, which the company says can be used for testing for drug compatibility faster. It was founded in 2019 and is headquartered in Durham,North Carolina.
  • Elegen — Elegen is powering the bioeconomy with high-accuracy DNA synthesis that delivers industry-leading speed, length, and quality.
  • Zafrens — Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.
Sahsen Ventures VC Fund · Seattle, Washington, United States
Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.
Show more
Investment focus
  • Biotechnology, Health Care, Non Profit
  • Funding Round, Series A, Seed
  • United States, China, Ghana
Portfolio highlights
  • Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
  • Monod Bio — Monod Bio l Simple. Powerful. Biosensors for Medicine & Biotech.
  • Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
5AM Ventures VC Fund · Menlo Park, California, United States · 7 investments in the past 12 months
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Silence Therapeutics — Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetictoolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types.
  • Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.
  • Adverum Biotechnologies — At Adverum, we are driven to establish ocular gene therapy as a new standard of care for debilitating retinal diseases.
MPM Capital VC Fund · Cambridge, Massachusetts, United States · 7 investments in the past 12 months
Powering Breakthroughs in Life Sciences
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
  • Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
  • Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies
Atlas Venture VC Fund · Cambridge, Massachusetts, United States · 11 investments in the past 12 months
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Korro Bio — Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in proteinstructure and function across multiple tissues.In 2018,
  • Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
  • Diagonal Therapeutics — Diagonal Therapeutics pioneers a new era in medicine by advancing agonist antibody therapeutics targeting the root causes of devastating diseases. Discover our ground-breaking approach to reactivate critical biological pathways for transformative patient outcomes.
DCVC VC Fund · San Francisco, California, United States · 13 investments in the past 12 months
We are deep tech venture capital.
Show more
Investment focus
  • Software, Artificial Intelligence, Health Care
  • Seed, Series A, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • Fervo Energy — Fervo Energy delivers 24/7 carbon-free energy through development of next-generation geothermal projects.
  • Kairos Aerospace — Kairos Aerospace provides large-scale, aerial monitoring of methane emissions. The company completed the first-ever basin-wide aerial survey for methane detection in its 2019 survey of the Permian Basin. Kairos Aerospace’s mission is to improve operational excellence for the oil and gas industry with cost-effective, efficient methane reductions atscale.
  • Relation Therapeutics — Relation uses machine learning to develop drugs for pressing unmet need.
KdT Ventures VC Fund · Austin, Texas, United States · 6 investments in the past 12 months
KdT Ventures is the standard for early-stage frontier science investing.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, Israel, Germany
Portfolio highlights
  • Elegen — Elegen is powering the bioeconomy with high-accuracy DNA synthesis that delivers industry-leading speed, length, and quality.
  • Motif Neurotech — Motif Neurotech is a company that develops minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses.
  • Radar Therapeutics — Precision-targeted, smart therapies to conquer the world's most intractable diseases.
Civilization Ventures VC Fund · San Francisco, California, United States · 4 investments in the past 12 months
DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, United Kingdom, Brazil
Portfolio highlights
  • Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
  • DermBiont — Leading a Revolution in Dermatology
  • Aperiam Bio — Aperiam Bio partners with enzyme engineers and distributors to create and share stabilized, solubilized, and catalytically optimized proteins. The company was founded in 2021 and is headquartered in Austin, Texas, United States.
Andreessen Horowitz VC Fund · Menlo Park, California, United States · 111 investments in the past 12 months
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more
Investment focus
  • Software, Information Technology, Internet
  • Series A, Seed, Series B
  • United States, United Kingdom, Canada
Portfolio highlights
  • xAI — XAI is an AI company that develops a platform to accelerate human scientific discovery. The company primarily focuses on developing advanced AI systems that are truthful, competent, and maximally beneficial for all of humanity. Its mission is to understand the true nature of the universe.
  • ZeroMark — ZeroMark is a defense product company building technology to ensure safety and precision when using kinetic and non lethal weapons.
  • Valar Labs — AI to Make Oncologists Smarter
Google Ventures VC Fund · Mountain View, California, United States · 57 investments in the past 12 months
GV supports innovative founders moving the world forward.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series A, Series B, Seed
  • United States, United Kingdom, Canada
Portfolio highlights
  • Vercel — Vercel's Frontend Cloud gives developers the frameworks, workflows, and infrastructure to build a faster, more personalized web.
  • Verse — Define & achieve your financial and emissions reduction goals with Aria, a software platform that helps companies buy and manage clean power.
  • WitnessAI — WitnessAI - Enable safe, effective AI
SR One VC Fund · Cambridge, Massachusetts, United States · 5 investments in the past 12 months
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Avalyn Pharma — This does NOT display on the home page
  • Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
  • Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases
Rev1 Ventures VC Fund · Columbus, Ohio, United States · 10 investments in the past 12 months
Rev1 Ventures provides seed stage venture capital funding in Columbus, Ohio along with startup services, space, mentoring, and connections. Learn more!
Show more
Investment focus
  • Software, Health Care, Information Technology
  • Seed, Series A, Funding Round
  • United States, Germany
Portfolio highlights
  • Trace — Trace is the simplest way ever to create AR content and experiences for your product and business.
  • Champ — Through the application of its secure, patent-pending technology, CHAMPtitles ends the reliance on legacy systems to manage U.S. automobile titles. CHAMPtitles partners with each party in the vehicle title ecosystem to reduce their costs in handling titles, turning the burdensome administrative process of issuing a vehicle title into a profitableactivity.
  • Niobium Microsystems — Niobium Microsystems creates custom integrated circuit and microelectronic system solutions for clients with complex power, performance, and security constraints.
Versant Ventures VC Fund · Menlo Park, California, United States · 7 investments in the past 12 months
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, Switzerland, Canada
Portfolio highlights
  • Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
  • SixPeaks Bio — SixPeaks is developing a pipeline of medicines for healthy weight loss.
  • Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Longwood Fund VC Fund · Boston, Massachusetts, United States · 4 investments in the past 12 months
Longwood creates and invests in science-based companies that develop novel solutions for important medical problems
Show more
Investment focus
  • Biotechnology, Therapeutics, Health Care
  • Series A, Series B, Series C
  • United States, United Kingdom, Italy
Portfolio highlights
  • Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
  • Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
  • BridgeBio Oncology Therapeutics — BridgeBio Oncology Therapeutics operates as a biopharmaceutical company.
Playground Global VC Fund · Palo Alto, California, United States · 7 investments in the past 12 months
Playground is an early-stage investment firm that helps old and new investors and entrepreneurs working at the intersection of bits, atoms, and AI. It focuses on investment, innovation, connected hardware, artificial intelligence, and robotics.
Show more
Investment focus
  • Software, Robotics, Artificial Intelligence
  • Series A, Seed, Series B
  • United States, Canada, France
Portfolio highlights
  • Boxbot — Dynamic storage and retrieval platform that adapts to varying cubic dimensions and eliminates manual pick stations.
  • Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
  • Element Zero — Element Zero - The Green Metal Company. Element Zero has developed a novel approach to cost-effectively and efficiently convert metal ores such as iron ore, nickel ore and other future facing metals, to pure metal form with zero carbon emissions.
Apple Tree Partners VC Fund · New York, New York, United States · 3 investments in the past 12 months
ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategicinsight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, Canada, United Kingdom
Portfolio highlights
  • Aulos Bioscience — Aulos Bioscience is a immuno-oncology company revolutionizing cancer care through the development of best-in-class IL-2 therapeutics. Learn more.
  • Ascidian Therapeutics — Ascidian is redefining the treatment of disease by rewriting RNA.
  • Deep Apple Therapeutics — Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen.
iSelect Fund VC Fund · St Louis, Missouri, United States
Venture investing in Food, Health, and AgTech. A generational investment thesis. Food is Health is longevity
Show more
Investment focus
  • Biotechnology, Health Care, Agriculture
  • Seed, Series A, Series B
  • United States, Australia
Portfolio highlights
  • MEND — Mend is the scientifically proven way to heal and enhance your body faster.
  • Triplebar — Triplebar provides sustainability, biotechnology, and synthetic biology research.
  • Pluton Biosciences — The miniscule organisms Pluton Biosciences discover possess the power to create global change. Pluton quickly and inexpensively taps into the diverse world of bacteria, fungi and viruses to discover next-generation products for carbon sequestration, agriculture, pharmaceutical, biomaterials and bioremediation.Pluton Bioscience's discoveryprocess generates diverse commercialization options, including: Organisms (biological products), Small Molecule Chemistries (fermentable and non-fermentable) and New Traits (scale dependent).
New Enterprise Associates VC Fund · Menlo Park, California, United States · 44 investments in the past 12 months
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series B, Series A, Series C
  • United States, India, China
Portfolio highlights
  • Faircado — Stop wasting time and money - faircado helps you find the best pre-owned deals for your wallet and the planet.
  • Twelve Labs — Twelve Labs helps developers make programs that can see, listen, and understand the world as we do by giving them the most powerful video search API
  • Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
Vivo Capital VC Fund · Palo Alto, California, United States · 12 investments in the past 12 months
Vivo Capital is a healthcare focused investment firm formed in 1996 that is currently making investments from its $1.4B Vivo Capital Fund IX into promising private healthcare companies and from its $635M Vivo Opportunity Fund into promising public healthcare companies.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series C, Series A
  • United States, China, United Kingdom
Portfolio highlights
  • Ajax Therapeutics — Ajax Therapeutics is an NYC-based biotechnology company applying computational chemistry and structure-based technologies to develop novel small molecules for hematologic malignancies
  • Silence Therapeutics — Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetictoolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types.
  • Adverum Biotechnologies — At Adverum, we are driven to establish ocular gene therapy as a new standard of care for debilitating retinal diseases.
Lux Capital VC Fund · New York, New York, United States · 42 investments in the past 12 months
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series A, Seed, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • LabGenius — Finding the next generation of drugs with machine learning, synthetic biology and laboratory automation
  • Maven AGI — Maven AGI is a technology company that focuses on the development of modern artificial intelligence (AI) solutions. Their primary aim is to reimagine the customer support experience by leveraging AI to lower costs, improve speed and quality, and drive efficiency. Their AI solutions are designed to unlock human potential by enabling teams to be moreproductive and giving them time back to do the work only humans can do. They also offer a range of services including customer acquisition strategy and operational planning. The company has a team size of 50 employees, with roles ranging from product management to sales and marketing.
  • Layup Parts — Layup is reshaping the composites industry by utilizing technology to manufacture high quality composite parts faster and more affordable than anyone else.
Flagship Pioneering VC Fund · Cambridge, Massachusetts, United States · 10 investments in the past 12 months
We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series C, Series A
  • United States, Canada, United Kingdom
Portfolio highlights
  • Inari — Inari is a biotech seed company that embraces diversity in every aspect of its business to drive innovation and help build a new food system. Our technology matches the complexity of nature using predictive design and multiplex gene editing to unlock the full potential of seed. We are always innovating, pushing the boundaries of what’s possible.Our SEEDesign platform is our point of distinction, using unsurpassed technology to enhance any crop for any geography to develop step-change products with a clear go-to-market approach.
  • Prologue Medicines — Prologue is systematically discovering the therapeutic potential of secreted proteins tuned through millennia of natural evolution to rapidly create powerful new medicines.
  • Syros Pharmaceuticals — Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiencythat is not well represented in pharmaceutical R&D.Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
The Column Group VC Fund · San Francisco, California, United States · 7 investments in the past 12 months
The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • Kenai Therapeutics — Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders. The company provides off-the-shelf neuron replacement medicines as effective disease-modifying treatments for neurological disorders, providing doctors with techniques to treat diseases like Parkinson's.
  • Accent Therapeutics — Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth anddifferentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients.
  • Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Horizons Ventures VC Fund · Hong Kong, Hong Kong Island, Hong Kong · 17 investments in the past 12 months
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more
Investment focus
  • Biotechnology, Artificial Intelligence, Software
  • Series A, Series B, Seed
  • United States, United Kingdom, Canada
Portfolio highlights
  • Fano Labs — We are one of the leading AI companies specialising on Language AI technologies for enterprises in customer services, compliance and other lines of businesses.
  • Voyage Foods — Voyage Foods has made sustainable and scalable alternatives to foods that have current obstacles –environmental, social, and health alike. Our breakthrough technology provides endless opportunities to make delicious, nearly identical, versions of beloved foods, without compromising individual health or our planet. We replicated the world’s favoritefoods so that we can all enjoy them, forever.
  • Cauldron Ferm — Cauldron is sustainably delivering the precision fermented prototypes of today to the supermarket shelves of tomorrow.
Connecticut Innovations VC Fund · Rocky Hill, Connecticut, United States · 13 investments in the past 12 months
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more
Investment focus
  • Health Care, Biotechnology, Software
  • Seed, Series A, Funding Round
  • United States, Israel, Canada
Portfolio highlights
  • Conduce Health — Conduce Health is a multi-specialty value-based care marketplace providing turnkey solutions for primary care organizations.
  • DeepLook Medical — Enhancing Medical Imaging with Revolutionary Software: DeepLook Medical envisions a future where data-driven imaging enables accurate, efficient, and personalized care across the entire treatment pathway.
  • Manifest Technologies — Manifest Technologies advances AI-powered computational neuroimaging system that quantifies neural and symptom data.
Roche Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, United Kingdom, Spain
Portfolio highlights
  • DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
  • Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
  • Bonum Therapeutics — Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.
Breakout Ventures VC Fund · San Francisco, California, United States · 2 investments in the past 12 months
Breakout Ventures is a new, early stage fund that backs bold scientist entrepreneurs working at the intersections of technology, biology, materials, and energy.
Show more
Investment focus
  • Biotechnology, Life Science, Therapeutics
  • Seed, Series B, Series A
  • United States
Portfolio highlights
  • Parallel Bio — Using the immune system to cure disease. Parallel Bio uses a human immune system in a dish and AI to discover drugs more likely to work in patients.
  • TFC Therapeutics — TFC Therapeutics is a biotechnology company developing novel biologics to target and eliminate key drivers of cancer.
  • EnPlusOne Biosciences — EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.
Illumina Ventures VC Fund · Foster City, California, United States · 8 investments in the past 12 months
We invest in companies that are advancing the field of genomics and pioneering new applications in healthcare, agriculture, environmental science, and personal
Show more
Investment focus
  • Biotechnology, Health Care, Life Science
  • Series A, Series B, Series C
  • United States, United Kingdom, France
Portfolio highlights
  • Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
  • Tagomics — Tagomics transform disease diagnosis through comprehensive multitopic profiling.
  • Attovia Therapeutics — Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated.
Dolby Family Ventures VC Fund · San Francisco, California, United States · 7 investments in the past 12 months
Dolby Family Ventures is an early stage venture firm focused on building great technology companies. They partner with best-in-class innovators and strong investment syndicate partners at the seed stage of a company’s development. Unlike many seed investors, They intend to continue to invest across future rounds in our successful portfoliocompanies.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Seed, Series B
  • United States, Austria, Israel
Portfolio highlights
  • LeoLabs — LeoLabs' network of ground-based, phased array radars produces high-resolution data on objects in LEO, supporting satellite service industries.
  • Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
  • Esper Satellite Imagery — Welcome to Esper Satellite Imagery. Enjoy your Stay.
Artis Ventures (AV) VC Fund · San Francisco, California, United States · 9 investments in the past 12 months
Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.
Show more
Investment focus
  • Health Care, Biotechnology, Software
  • Series A, Series B, Seed
  • United States, India, Germany
Portfolio highlights
  • Rad AI — Made for Radiologists, by Radiologists. Empowering radiologists with AI to save time, reduce burnout, and improve patient care.
  • Freenome — Freenome is a biotechnology company based in South San Francisco that has pioneered the most comprehensive multiomics platform for early cancer detection with a simple blood test.
  • OverT Bio — OverT Bio A new age in cell therapy
Foresite Capital VC Fund · San Francisco, California, United States · 7 investments in the past 12 months
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series C, Series A
  • United States, United Kingdom, Australia
Portfolio highlights
  • Cullinan Therapeutics — Our goal is to develop therapeutics that will dramatically improve the standard-of-care for those with cancer.
  • Xaira Therapeutics — Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research tobetter understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
  • Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.
Alumni Ventures VC Fund · Manchester, New Hampshire, United States · 150 investments in the past 12 months
Alumni Ventures offers diversified venture portfolios to accredited investors into highly competitive deals that individuals typically do not have access to on their own.
Show more
Investment focus
  • Software, Information Technology, Health Care
  • Seed, Series A, Series B
  • United States, United Kingdom, Canada
Portfolio highlights
  • CaseMark — CaseMark revolutionizes legal processes with its AI-driven Workflow platform, streamlining routine tasks while upholding the highest standards of privacy and security. Powered by advanced models like GPT-3.5 and GPT-4 turbo, and hosted on the robust Azure infrastructure, it's the trusted choice for modern legal professionals. With CaseMark, efficiency meets excellence in every legal operation.
  • TransCrypts — We all have that file box where we throw all our important documents. Our goal at TransCrypts is to make that box digital and have all the documents secured through the blockchain. We currently offer industry leading privacy and security standards on our file storage and sharing platform and have solutions for individuals all the way to enterprises.
  • Frore Systems — Frore Systems is a operator of an engineering company intended to offer micro electromechanical systems.The company is currently operating in a Stealth mode.
Felicis VC Fund · Menlo Park, California, United States · 33 investments in the past 12 months
Backing founders building iconic companies that transcend boundaries
Show more
Investment focus
  • Software, SaaS, Health Care
  • Series A, Seed, Series B
  • United States, Canada, Germany
Portfolio highlights
  • Tines — Tines is an enterprise automation platform designed to help security and ops teams automate manual workloads. With 1,000+ template options for common security actions, Tines is power and simplicity through direct integration with your existing tools. The company was founded in 2018 and is headquartered in Dublin.
  • Midi Health — Expert care for women 40+. Made for midlife. Delivered by experienced clinicians. Covered by insurance. Book a visit today.
  • Edia Learning — Edia is an EdTech platform for 6-12 Math that ensures superior state test outcomes.
Omega Funds VC Fund · Boston, Massachusetts, United States · 3 investments in the past 12 months
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • ARTBIO — ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports.
  • Beta Bionics — Improving lives of people living with diabetes by helping to reduce the data and decision-making overload required with diabetes.
  • Upstream Bio — Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio was founded in 2004 and was headquartered in the United States.
RiverVest VC Fund · St Louis, Missouri, United States · 4 investments in the past 12 months
RiverVest is a leading venture capital firm building life science companies to address significant unmet medical needs.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States
Portfolio highlights
  • Biolinq — Introducing a revolutionary platform for metabolic health.
  • Engrail Therapeutics — Engrail delivers transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and neurodevelopmental disorders.
  • Sparrow Pharmaceuticals — Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess.
AbbVie Biotech Ventures VC Fund · North Chicago, Illinois, United States
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, China, Italy
Portfolio highlights
  • Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
  • Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
  • DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Oreilly AlphaTech Ventures VC Fund · San Francisco, California, United States
O'Reilly AlphaTech Ventures (OATV) is in the business of funding disruptors, innovators, and hackers of the status quo. From open source to the early days of the web and its recent resurgence, O'Reilly Media has played a key role as trend spotter and advocate for putting world-changing technologies on the map. OATV effort is to bring thelegacy, resources, and relationships of O'Reilly to each investment they make.
Show more
Investment focus
  • Software, E-Commerce, Analytics
  • Series A, Seed, Series B
  • United States, United Kingdom, Canada
Portfolio highlights
  • Pachama — Harnessing AI to drive carbon capture and protect global forests
  • Videra Health — See People Differently Proactively engage patients anytime, anywhere with our AI-powered patient assessment and monitoring solution. Providers and payors save time and resources while improving outcomes and reducing costs. With Videra Health, proactive care drives measurable results Learn more See People Differently Proactively engage patients anytime, anywhere with our AI-powered patient assessment and monitoring solution.
  • Impart Security — Real-time API Security spanning discovery, monitoring, and enforcement.
Vida Ventures VC Fund · Boston, Massachusetts, United States · 5 investments in the past 12 months
Vida Ventures’ mission is to bring science to life by advancing transformative biomedical innovations that have the potential to make a meaningful impact on the lives of patients. They want to do well by doing good for others. Vida Ventures is a bicoastal life sciences company building and investment firm, founded in 2017 by a group of scientists,physicians, entrepreneurs, and investors who are passionate about building and funding breakthroughs in biomedicine .
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, China, India
Portfolio highlights
  • Avalyn Pharma — This does NOT display on the home page
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
  • Alterome Therapeutics — Transforming the lives of cancer patients, one alteration at a time. Our Mission is to discover precise therapies and inspire hope for individuals affected by cancer.
Two Sigma Ventures VC Fund · New York, New York, United States · 9 investments in the past 12 months
We are an early-stage venture capital firm investing in transformative companies harnessing information growth and computing power to change the world.
Show more
Investment focus
  • Software, Machine Learning, Artificial Intelligence
  • Series A, Seed, Series B
  • United States, Canada, Mexico
Portfolio highlights
  • treet — Treet helps brands launch fully-branded recommerce sites where customers can buy & sell items from each other.
  • Anomalo — Anomalo allows users to continuously inspect and validate the data coming into their warehouses.
  • Cosmos Innovation — Cosmos Innovation specialize in full stack software development, product design, cloud hosting, and MVP deployment.
JDRF T1D Fund VC Fund · Boston, Massachusetts, United States · 3 investments in the past 12 months
The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Funding Round
  • United States, Italy, Canada
Portfolio highlights
  • DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
  • SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.
  • Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Boxer Capital VC Fund · Windermere, Florida, United States · 6 investments in the past 12 months
Boxer Capital caters to public companies based in the biotechnology industry.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Post-IPO Equity, Series C
  • United States, Canada, United Kingdom
Portfolio highlights
  • Ajax Therapeutics — Ajax Therapeutics is an NYC-based biotechnology company applying computational chemistry and structure-based technologies to develop novel small molecules for hematologic malignancies
  • Protara Therapeutics — Protara Therapeutics develops transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy created for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipidsubstrate replacement therapy for the treatment of intestinal failure-associated liver disease.The Protara team prioritizes creativity, diverse perspectives, and tenacity to expedite their goal of bringing life-changing therapies to people with limited treatment options.
  • Jasper Therapeutics — Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant.
Investors by industry
Investors by country
Investors in United States by industry